Senseonics in the Spotlight: A Preliminary 2025 Wrap and a 2026 Pivot That Might Reshape the CGM Play

By a seasoned financial journalist, channeling the spirit of Matt Levine — with ticker SENS in the mix and a close eye on EPS, earnings expectations, and the revenue forecast ahead.

Overview: Preliminary numbers raise questions about direction and cadence

Senseonics Holdings, Inc. (ticker: SENS) released a briefing on preliminary, unaudited results for the fourth quarter of 2025 and offered a 2026 business outlook. The press release emphasizes revenue momentum—specifically, about $14.2 million for Q4 2025, with trailing full-year 2025 revenue around $35.2 million. Management notes the figures are unaudited and subject to year-end close processes, a standard caveat that still leaves investors with a cleaner, if still provisional, read on the company’s trajectory.

The document doubles as a strategic update: it signals a major transition in commercial duties in 2026, with Ascensia Diabetes Care set to assume U.S. commercialization and distribution of Eversense starting January 1, 2026. The company also points to a 2026 revenue forecast in the $58–$62 million range and a gross margin target around 50% for the year. If you’re tracking EPS and the earnings surprise calculus, this release is a reminder that the next reported results could reflect a different cost structure and channel mix than 2025.

Key operational highlights

Preliminary Q4 2025 revenue: approximately $14.2 million; preliminary full-year 2025 revenue: approximately $35.2 million, up strongly year over year.
U.S. new patient growth in Q4 2025: 103% vs. Q4 2024, driven by direct-to-consumer marketing and a record pace of new patient additions.
IDE approval from the FDA to begin a pivotal trial for the self-powered Gemini sensor; first patients enrolled.
Commercialization and distribution transition: Ascensia to take over Eversense commercialization in the U.S. beginning Jan 1, 2026.
Launch-related milestones: anticipated CE mark for Eversense 365 in Europe; twiist system integration with Eversense compatibility; Gemini trial expected to complete in late 2026.

Outlook and forward-looking notes

Senseonics guided full-year 2026 net revenue in the range of $58–$62 million, implying a robust expansion versus 2025 as the company pivots its go-to-market strategy through Ascensia and scales new product and integration efforts. Gross margin is targeted near 50% for the year, a signal that management aims to stabilize margins amid channel realignment and product transitions.

The company plans to provide more detail on its 2026 expectations during the March 2, 2026 earnings call, where it will also discuss the fourth quarter and full-year results. Importantly, the current numbers are preliminary; investors should be prepared for revision after the close of books.

Strategic read-through: what this means for Senseonics and its peers

The headline story isn’t just the revenue numbers; it’s the channel transformation. The Ascensia deal to take over U.S. commercialization and distribution of Eversense marks a strategic outsourcing of a substantial portion of Senseonics’ domestic go-to-market burden. That could free up resources for R&D and provide scale economics if the partners execute effectively. But it also introduces a dependency risk: will European and U.S. execution align with the incremental revenue forecast?

From a financial storytelling perspective, the numbers invite an EPS discussion that the release doesn’t fully resolve. Analysts will need to bridge the gap between unaudited quarterly results and the eventual year-end close to verify potential earnings per share (EPS) impact. Until then, any reference to earnings surprises remains a probabilistic exercise—an anticipation of whether the final results beat or miss the consensus after adjustments.

Beyond Senseonics, the broader CGM landscape could feel the ripple effects of this transition. If the U.S. market can sustain high patient growth and if the Gemini trial and Eversense 365 programs move toward milestones as planned, peers may recalibrate expectations for regulatory timelines, commercial partnerships, and cost structures—especially for players balancing direct and partner-driven channels.

Financial snapshot in context

The reported figures underscore meaningful growth versus prior periods, with a standout year-over-year acceleration in Q4 2025 revenue. The 103% U.S. patient growth aligns with stronger patient acquisition channels, notably DTC marketing, hinting at a more favorable demand environment for long-term CGM adoption.

The 2026 revenue forecast of $58–$62 million implies a substantial top-line lift, but the margin profile (target gross margin around 50%) will be a key determinant of profitability. Investors will want to see how the Ascensia transition affects operating expenses, sales and marketing spend, and implementation costs tied to the European market handoff and the Eversense 365 program.

Earnings context: what to watch for EPS and surprises

While the release focuses on revenue and milestones, equity holders will instinctively look for EPS implications once the quarterly and annual close is complete. In earnings language, an EPS consensus will matter, and any earnings surprise—whether to the upside or downside—could hinge on cost control during the transition and the pace of adoption for the new commercial framework.

The absence of explicit EPS figures in the press release doesn’t derail the narrative; it shifts the risk to the upcoming results. If Senseonics delivers on the $58–$62 million revenue target with a stable or improved gross margin, the implied EPS trajectory could benefit from better fixed-cost absorption and a leaner go-to-market in some regions. Conversely, if regulatory or integration delays appear, the EPS path could face pressure even as revenue scales.

Sector implications: where this leaves the CGM peers and investors

The Senseonics update is a reminder that the CGM sector continues to blend technology, regulatory clearance, and commercial partnerships as key value drivers. The Gemini and Eversense 365 programs represent optionality: if pivotal trials succeed and CE approvals arrive on schedule, Senseonics could unlock higher revenue potential with improved user experience—potentially a lever for higher gross margins if manufacturing and logistics scale efficiently.

For peers, the message is twofold. First, channel strategies matter as much as product capability; partnerships like Ascensia could redefine regional competitive advantages. Second, capital allocation remains critical; a company pinning its long-term growth to regulatory milestones must manage near-term profitability and cash burn with discipline, especially when the near-term revenue base is still relatively modest.

Conclusion: a pivotal year ahead for Senseonics

Senseonics’ Q4 2025 preliminary results and 2026 outlook sketch a path where demand momentum aligns with a strategic realignment of commercial responsibilities. The revenue forecast signals ambition, while the Ascensia partnership introduces both scale and execution risk. For investors tracking SENS, the coming quarters will test whether the blended engine of DTC-driven patient growth and strategic distribution can deliver on the elevated revenue trajectory without sacrificing margin discipline.

In a market where “earnings surprise” is a probabilistic event, the key will be whether Senseonics can translate the topline momentum into a stable EPS outcome and whether the 2026 catalysts—Eversense 365 CE clearance, the Gemini trial, and the integrated twiist system—arrive on schedule. The tick-by-tick drama of the quarterly close may not be as glamorous as a blockbuster product launch, but it will tell you how sustainable this revenue forecast really is.